Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Versatile synthetic alternatives to Matrigel for vascular toxicity screening and stem cell expansion.

Nguyen EH, Daly WT, Le NNT, Farnoodian M, Belair DG, Schwartz MP, Lebakken CS, Ananiev GE, Saghiri MA, Knudsen TB, Sheibani N, Murphy WL.

Nat Biomed Eng. 2017;1. pii: 0096. doi: 10.1038/s41551-017-0096. Epub 2017 Jul 11.

2.

High-Content Assay Multiplexing for Vascular Toxicity Screening in Induced Pluripotent Stem Cell-Derived Endothelial Cells and Human Umbilical Vein Endothelial Cells.

Iwata Y, Klaren WD, Lebakken CS, Grimm FA, Rusyn I.

Assay Drug Dev Technol. 2017 Aug/Sep;15(6):267-279. doi: 10.1089/adt.2017.786. Epub 2017 Aug 3.

3.

LRRK2 kinase activity and biology are not uniformly predicted by its autophosphorylation and cellular phosphorylation site status.

Reynolds A, Doggett EA, Riddle SM, Lebakken CS, Nichols RJ.

Front Mol Neurosci. 2014 Jun 24;7:54. doi: 10.3389/fnmol.2014.00054. eCollection 2014.

4.

Transformation of in vitro tools for kinase profiling: keeping an eye over the off-target liabilities.

Bi K, Lebakken CS, Vogel KW.

Expert Opin Drug Discov. 2011 Jul;6(7):701-12. doi: 10.1517/17460441.2011.575776. Epub 2011 Apr 12.

PMID:
22650978
5.

Detection of allosteric kinase inhibitors by displacement of active site probes.

Lebakken CS, Reichling LJ, Ellefson JM, Riddle SM.

J Biomol Screen. 2012 Jul;17(6):813-21. doi: 10.1177/1087057112439889. Epub 2012 Mar 26.

PMID:
22453235
6.

Multi-pathway cellular analysis of compound selectivity.

Hancock MK, Lebakken CS, Wang J, Bi K.

Mol Biosyst. 2010 Oct;6(10):1834-43. doi: 10.1039/c003669b. Epub 2010 Jun 30.

PMID:
20593073
7.

Development and applications of a broad-coverage, TR-FRET-based kinase binding assay platform.

Lebakken CS, Riddle SM, Singh U, Frazee WJ, Eliason HC, Gao Y, Reichling LJ, Marks BD, Vogel KW.

J Biomol Screen. 2009 Sep;14(8):924-35. doi: 10.1177/1087057109339207. Epub 2009 Jun 29.

PMID:
19564447
8.

Sarcoglycan complex: implications for metabolic defects in muscular dystrophies.

Groh S, Zong H, Goddeeris MM, Lebakken CS, Venzke D, Pessin JE, Campbell KP.

J Biol Chem. 2009 Jul 17;284(29):19178-82. doi: 10.1074/jbc.C109.010728. Epub 2009 Jun 3.

9.

Pharmacological characterization of purified recombinant mTOR FRB-kinase domain using fluorescence-based assays.

Reichling LJ, Lebakken CS, Riddle SM, Vedvik KL, Robers MB, Kopp LM, Bruinsma R, Vogel KW.

J Biomol Screen. 2008 Mar;13(3):238-44. doi: 10.1177/1087057108314609.

PMID:
18354135
10.

A fluorescence lifetime based binding assay to characterize kinase inhibitors.

Lebakken CS, Hee Chol Kang, Vogel KW.

J Biomol Screen. 2007 Sep;12(6):828-41. Epub 2007 Jul 20.

PMID:
17644772
11.

An improved beta-lactamase reporter assay: multiplexing with a cytotoxicity readout for enhanced accuracy of hit identification.

Hallis TM, Kopp AL, Gibson J, Lebakken CS, Hancock M, Van Den Heuvel-Kramer K, Turek-Etienne T.

J Biomol Screen. 2007 Aug;12(5):635-44. Epub 2007 May 21.

PMID:
17517902
12.

Analysis of ligand-dependent recruitment of coactivator peptides to estrogen receptor using fluorescence polarization.

Ozers MS, Ervin KM, Steffen CL, Fronczak JA, Lebakken CS, Carnahan KA, Lowery RG, Burke TJ.

Mol Endocrinol. 2005 Jan;19(1):25-34. Epub 2004 Sep 16.

PMID:
15375189
13.

A high throughput screening assay to screen for CYP2E1 metabolism and inhibition using a fluorogenic vivid p450 substrate.

Marks BD, Smith RW, Braun HA, Goossens TA, Christenson M, Ozers MS, Lebakken CS, Trubetskoy OV.

Assay Drug Dev Technol. 2002 Nov;1(1 Pt 1):73-81.

PMID:
15090158
14.

Syndecan-1 signals independently of beta1 integrins during Raji cell spreading.

Lebakken CS, McQuade KJ, Rapraeger AC.

Exp Cell Res. 2000 Sep 15;259(2):315-25.

PMID:
10964499
15.

Sarcospan-deficient mice maintain normal muscle function.

Lebakken CS, Venzke DP, Hrstka RF, Consolino CM, Faulkner JA, Williamson RA, Campbell KP.

Mol Cell Biol. 2000 Mar;20(5):1669-77.

16.

Membrane targeting and stabilization of sarcospan is mediated by the sarcoglycan subcomplex.

Crosbie RH, Lebakken CS, Holt KH, Venzke DP, Straub V, Lee JC, Grady RM, Chamberlain JS, Sanes JR, Campbell KP.

J Cell Biol. 1999 Apr 5;145(1):153-65.

17.

Progressive muscular dystrophy in alpha-sarcoglycan-deficient mice.

Duclos F, Straub V, Moore SA, Venzke DP, Hrstka RF, Crosbie RH, Durbeej M, Lebakken CS, Ettinger AJ, van der Meulen J, Holt KH, Lim LE, Sanes JR, Davidson BL, Faulkner JA, Williamson R, Campbell KP.

J Cell Biol. 1998 Sep 21;142(6):1461-71.

18.

Pervanadate activation of intracellular kinases leads to tyrosine phosphorylation and shedding of syndecan-1.

Reiland J, Ott VL, Lebakken CS, Yeaman C, McCarthy J, Rapraeger AC.

Biochem J. 1996 Oct 1;319 ( Pt 1):39-47.

19.

Syndecan-1 mediates cell spreading in transfected human lymphoblastoid (Raji) cells.

Lebakken CS, Rapraeger AC.

J Cell Biol. 1996 Mar;132(6):1209-21.

Supplemental Content

Loading ...
Support Center